Central Nervous System Partnering Terms and Agreements -





Published: August 2014 | Pages: 595

The Central Nervous System Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the central nervous system partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter central nervous system partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors central nervous system technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

                                

This report contains over 1,500 links to online copies of actual central nervous system deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of central nervous system dealmaking and business activities. Chapter 1 provides an introduction to the report.

 

Chapter 2 provides an overview of the trends in central nervous system dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

                             

Chapter 3 provides a review of the leading central nervous system deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of central nervous system deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides comprehensive access to all central nervous system deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive directory of all central nervous system partnering deals signed and announced since 2009. The chapter is organized by specific central nervous system therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided with each report of all central nervous system partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in central nervous system partnering and dealmaking since 2009.

                                                  

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of central nervous system technologies and products.


 

Executive Summary 

                 

Chapter 1 – Introduction 

  

Chapter 2 – Trends in central nervous system dealmaking 

 

2.1. Introduction

2.2. Central nervous system partnering over the years

2.3. Bigpharma central nervous system dealmaking activity

2.4. Bigpharma not active in Central nervous system

2.5. Central nervous system partnering by deal type     

2.6. Central nervous system partnering by industry sector

2.7. Central nervous system partnering by stage of development

2.8. Central nervous system partnering by technology type

2.9. Central nervous system partnering by CNS indication

2.10. Average deal terms for central nervous system

2.10.1 Central nervous system headline values 

2.10.2 Central nervous system upfront payments

2.10.3 Central nervous system milestone payments      

2.10.4 Central nervous system royalty rates

 

Chapter 3 – Leading central nervous system deals 

 

3.1. Introduction

3.2. Top central nervous system deals by value

3.3. Top central nervous system deals involving bigpharma

 

Chapter 4 – Bigpharma central nervous system deals 

 

4.1. Introduction

4.2. How to use bigpharma partnering deals

4.3. Bigpharma central nervous system partnering company profiles

Abbott 

Actavis

Allergan

Amgen

Aspen Pharmacare

Astellas           

AstraZeneca    

Baxter International

Bayer

Bayer Healthcare         

Bayer Schering Pharma           

Biogen Idec     

Boehringer Ingelheim   

Bristol-Myers Squibb   

CSL     

Daiichi Sankyo 

Dainippon Sumitomo

Dainippon Pharmaceutical

Eisai

Eli Lilly

Endo Pharmaceuticals 

Forest Laboratories      

Forest Laboratories Ireland

GlaxoSmithKline          

Hospira

Johnson & Johnson      

Kyowa Hakko Kirin       

Lundbeck         

Merck & Co     

Merck KGaA    

Mylan  

Novartis          

Otsuka

Pfizer  

Purdue

Roche 

Genentech       

Sanofi  

Servier

Shionogi          

Shire   

Takeda

Teva   

UCB    

Valeant

Watson

                                              

Chapter 5 – Central nervous system partnering contracts directory 

 

5.1. Introduction           

5.2. By deal type          

Asset purchase

Assignment     

Bigpharma outlicensing

Co-development           

Collaborative R&D

Co-market       

Contract service

Co-promotion   

Development   

Distribution      

Equity purchase           

Grant   

Interests          

Joint venture    

Licensing         

Litigation         

Loan    

Manufacturing  

Marketing        

Option

Promotion        

Research         

Royalty financing

Settlement       

Spin out           

Sub-license     

Supply

Termination     

Warranty         

5.3. By stage of development   

Discovery        

Formulation     

Marketed         

Phase I

Phase II           

Phase III          

Preclinical       

Regulatory       

5.4. By technology type

Analysis          

Assays

Biodefense

Biological compounds

Biomarkers      

Biomaterials    

Blood products 

Clinical testing

Devices           

Diagnostics     

Discovery tools

DNA probes     

Drug delivery

Enabling technology     

Equipment       

Facilities          

Genomics        

Implant

In vitro models 

Natural product

Oligonucleotide

Orphan drug    

Peptides          

Processes       

Proteomics

Radio/Chemo-therapy

Recombinant DNA       

Research services       

Research supplies       

RNA therapeutics         

Screening        

Small molecules          

Vaccines

                                                                       

Chapter 6 – Central nervous system dealmaking by indication 

 

6.1. Introduction

6.2. Deals by therapeutic indication

Central Nervous System          

Cerebral palsy 

Creutzfeldt Jakob disease        

Dizziness         

Epilepsy          

Guillain Barre syndrome           

Headache        

Meningitis        

Bacterial

Haemophilus influenzae Type B

Meningococcal

Mycobacterium tuberculosis

Pneumococcal

Fungal 

Viral    

Migraine          

Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease)

Multiple sclerosis

Nausea

Neuropathy

Pain    

Neuralgia         

Paralysis         

Parkinson's disease     

Restless leg syndrome

Spinal cord

Stroke 

Traumatic Brain Injury  

Vertigo

Weakness

 

Chapter 7 – Partnering resource center 

 

7.1. Online partnering   

7.2. Partnering events  

7.3. Further reading on dealmaking       

 

About Wildwood Ventures         

Current Partnering       

Current Agreements

Recent titles from CurrentPartnering     

Order Form – Reports  

Order Form – Therapy Reports 

 

Appendices 

 

Appendix 1 – Directory of central nervous system deals by company A-Z 2007-2012

Appendix 2 – Directory of central nervous deals by deal type 2007-2012

Appendix 3 – Directory of central nervous system deals by stage of development 2007-2012

Appendix 4 – Directory of central nervous system deals by technology type 2007-2012

Appendix 5 – Deal type definitions 

Table of figures 

 

Figure 1: Central nervous system partnering since 2009

Figure 2: Bigpharma – top 50 – Central nervous system deals 2007 to 2012

Figure 3: Bigpharma Central nervous system deal frequency – 2007 to 2012

Figure 4: Inactive bigpharma in CNS 2007-2012

Figure 5: Central nervous system partnering by deal type since 2009

Figure 6: Central nervous system partnering by industry sector since 2009       

Figure 7: Central nervous system partnering by stage of development since 2009          

Figure 8: Central nervous system partnering by technology type since 2009      

Figure 9: Central nervous system partnering by CNS target since 2009 

Figure 10: Central nervous system deals with a headline value  

Figure 11: Central nervous system deal headline value distribution, US$million – discovery stage

Figure 12: Central nervous system deal headline value distribution, US$million – preclinical stage

Figure 13: Central nervous system deal headline value distribution, US$million – phase I stage

Figure 14: Central nervous system deal headline value distribution, US$million – phase II stage

Figure 15: Central nervous system deal headline value distribution, US$million – phase III stage

Figure 16: Central nervous system deal headline value distribution, US$million – regulatory stage

Figure 17: Central nervous system deal headline value distribution, US$million – marketed stage   

Figure 18: Summary median headline value by stage of development, 2007-2012

Figure 19 Central nervous system deals with upfront payment values

Figure 20: Central nervous system deal upfront payment distribution, US$million – discovery stage

Figure 21: Central nervous system deal upfront payment distribution, US$million – preclinical stage

Figure 22: Central nervous system deal upfront payment distribution, US$million – phase I stage

Figure 23: Central nervous system deal upfront payment distribution, US$million – phase II stage

Figure 24: Central nervous system deal upfront payment distribution, US$million – phase III stage

Figure 25: Central nervous system deal upfront payment distribution, US$million – regulatory stage

Figure 26: Central nervous system deal upfront payment distribution, US$million – marketed stage

Figure 27: Summary median upfront payments by stage of development, 2007-2012

Figure 28: Central nervous system deals with milestone payments

Figure 29: Central nervous system deal milestone distribution, US$million – discovery stage

Figure 30: Central nervous system deal milestone distribution, US$million – preclinical stage

Figure 31: Central nervous system deal milestone distribution, US$million – phase I stage

Figure 32: Central nervous system deal milestone distribution, US$million – phase II stage

Figure 33: Central nervous system deal milestone distribution, US$million – phase III stage

Figure 34: Central nervous system deal milestone distribution, US$million – regulatory stage

Figure 35: Central nervous system deal milestone distribution, US$million – marketed stage

Figure 36: Central nervous system deals with royalty rates, %

Figure 37: Central nervous system deal royalty rate distribution, US$million – discovery stage

Figure 38: Central nervous system deal royalty rate distribution, US$million – preclinical stage

Figure 39: Central nervous system deal royalty rate distribution, US$million – phase I stage           

Figure 40: Central nervous system deal royalty rate distribution, US$million – phase II stage   

Figure 41: Central nervous system deal royalty rate distribution, US$million – phase III stage

Figure 42: Central nervous system deal royalty rate distribution, US$million – regulatory stage

Figure 44: Summary median royalty rate by stage of development, 2007-2012

Figure 45: Top central nervous system deals by value since 2009

Figure 46: Top central nervous system deals signed by bigpharma value since 2009

Figure 47: Online partnering resources

Figure 48: Forthcoming partnering events